Citations

Clear

6273 citation(s) found for "To, Andrew".

Nutrition Knowledge and Perceived Dietary Requirements of Adolescent Student-Athletes: A Pilot Study
Jagim, Andrew R. , Merfeld, Brandon , Ambrosius, Abby, Carpenter, Makenna, Fields, Jennifer B. , Jones, Margaret T. , Jagim, Andrew R , Fields, Jennifer B

Mayo Clinic

Nutrients | December 31, 2024 | Volume: 17 | Issue: 1 | Pages: 133

10.3390/nu17010133 | PMID 39796567 Get It

Background/Objectives: Adherence to sports-specific nutritional guidelines can help optimize athlete performance and health. However, adolescent athletes may not have adequate nutrition knowledge and understanding of specific nutritional requirements. The objective of the current study was to examine the nutrition knowledge and perceived dietary requirements of adolescent athletes. Methods: Male (n = 29, age: 15.7 ± 1.3 yrs.; height: 178.9 ± 8.3 cm; body mass: 74.7 ± 17.2 kg; body fat %: 13.9 ± 7.9%) and female (n = 15, age: 16.5 ± 1.4 yrs.; height: 169.9 ± 6.5 cm; body mass: 63.3 ± 4.5 kg; body fat %: 23.7 ± 3.8%) secondary school student-athletes completed body composition testing (hydrostatic weighing) and electronic surveys (Abridged Sports Nutrition Knowledge Questionnaire (ASNKQ); self-perception of dietary energy and macronutrient requirements). Results: Athletes demonstrated poor sports nutrition knowledge, with no differences observed between sexes for the number of questions answered correctly (males: 45.1 ± 9.8% vs. females: 43.1 ± 12.7%; p = 0.57). No relationships were observed between ASNKQ scores and body composition parameters or between ASNKQ scores and self-reported perception of dietary energy and macronutrient requirements (p > 0.05). Athletes self-reported a lower perceived energy (−560 ± 1272 kcal/d; p = 0.014) and carbohydrate intake (−73 ± 376 g/d; p = 0.014) requirement compared to calculated nutritional recommendations. Athletes self-reported a higher perceived protein intake (263 ± 586 g/d; p = 0.026) requirement compared to calculated nutritional requirements. Conclusions: The current sample of adolescent athletes from the secondary school level appears to have a poor level of sports nutrition knowledge and understanding of energy and macronutrient requirements.
Maintaining stability at the lumbosacral-pelvic region in adult spinal deformity surgery without sacroiliac joint fusion: are 4 pelvic screws superior to 2 pelvic screws?
Mohanty, Sarthak , Stephan, Stephen , Mikhail, Christopher , Platt, Andrew , Lewerenz, Erik , Lombardi, Joseph M. , Sardar, Zeeshan M. , Lehman, Ronald A. , Lenke, Lawrence G. , Bakhsheshian, Joshua , Hassan, Fthimnir M.

Mayo Clinic

Journal of Neurosurgery: Spine | December 28, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.3171/2024.8.spine231331 | PMID 39729578 Get It

OBJECTIVE The objective of this study was to compare a multiple pelvic screw fixation strategy (dual bilateral 4 pelvic screw fixation [4PvS]) with the use of single bilateral 2 pelvic screw fixation (2PvS), with the aim of addressing lumbosacral junction stability. METHODS This analysis is a single-center, retrospective review of ASD patients treated between 2015 and 2021. All patients had a minimum 2-year follow-up and spinal fusion to the sacrum without sacroiliac fusion and met at least one radiographic and procedural criterion: pelvic incidence–lumbar lordosis ≥ 20°, T1 pelvic angle ≥ 20°, sagittal vertical axis ≥ 7.5 cm, scoliosis ≥ 50°, three-column osteotomy, or spinal fusion of ≥ 8 levels. Two sacropelvic fixation methods were compared: 4PvS versus 2PvS. Primary outcomes included spinal implant-related reoperation and screw breakage, while secondary outcomes included reoperation for symptomatic pelvic screws, screw loosening or bending, L5–S1 pseudarthrosis, and patient-reported outcomes. Propensity score matching and inverse probability of treatment weighting (IPTW) were used to minimize selection bias and estimate causal treatment effects. Clinical outcomes were assessed using conditional multivariable logistic regression. RESULTS In this study of 406 patients (67.98% female, mean age 64.48 years), 349 patients (85.96%) received 2PvS and 57 (14.04%) received 4PvS. Age (OR 1.081, 95% CI 1.027–1.145) and total number of osteotomies (OR 1.180, 95% CI 1.048–1.355) emerged as independent predictors of receiving the 4PvS technique. In unmatched cohorts (n = 406), 2-year implant-related reoperation rates (p = 0.1896) and pelvic screw breakage rates (p = 0.2498) were not significantly different between groups. However, in the 4:1 propensity score–matched cohort, the 2-year reoperation rate (10.53% for 2PvS vs 3.51% for 4PvS; OR 3.27, 95% CI 1.10–9.74 [p = 0.0312]) and the pelvic screw breakage rate (9.21% for 2PvS vs 3.51% for 4PvS; OR 2.87, 95% CI 1.08–7.63 [p = 0.0349]) were significantly higher among the 2PvS groups. The IPTW analysis confirmed these findings, with reoperation rates of 10.45% for 2PvS and 1.18% for 4PvS (p = 0.0244) and pelvic screw breakage rates of 8.72% and 1.18%, respectively (p = 0.0477). A safety assessment revealed comparable operative times and intra- and perioperative complications between the two techniques. CONCLUSIONS Patients who underwent 4PvS demonstrated significantly lower 2-year implant-related reoperation and pelvic screw breakage rates compared with 2PvS, with no differences in intraoperative or perioperative complications.
Semaglutide-Associated Gastric Pneumatosis
Turunen, Arto , Coombs, Reilly A. , Garg, Sushil Kumar , Turunen, Andrew M.

Mayo Clinic

ACG Case Reports Journal | December 27, 2024 | Volume: 12 | Issue: 1 | Pages: e01579

10.14309/crj.0000000000001579 | PMID 39734391 Get It

ABSTRACT Semaglutide, a glucagon-like peptide-1 receptor agonist, used for Type 2 diabetes mellitus and more recently for weight loss, often causes gastrointestinal adverse effects such as delayed gastric emptying and abdominal discomfort. Current literature has not described an associated case of gastric pneumatosis with semaglutide use. We report a 61-year-old man on semaglutide for 9 months with gastric pneumatosis. Symptoms resolved on discontinuation. Clinicians should be vigilant for significant gastrointestinal adverse effects, including pneumatosis with semaglutide use.
Examining Changes in Ulnar Collateral Ligament Reconstruction Surgery Patterns Among Professional Baseball Players
Jones, Margaret T. , Erickson, Jacob L. , Taylor, Wayne A., Bittner, Michael , Jagim, Andrew R , Almonroeder, Thomas Gus , Taylor, Wayne A., Jagim, Andrew R.

Mayo Clinic

Clinical Journal of Sport Medicine | December 24, 2024 | Volume: 35 | Issue: 4 | Pages: 465-470

10.1097/jsm.0000000000001319 | PMID 39718384 Get It

Objective: To retrospectively analyze publicly available elbow ulnar collateral ligament reconstruction (UCLR) injury data for professional baseball players. Design: Descriptive epidemiology study. Setting: A retrospective analysis using an open-source database was performed. The database contained all known UCLR surgeries among Major League Baseball (MLB) and Minor League Baseball (MiLB) players. Participants: In total, 1801 professional male professional baseball pitchers (age: 24.5 ± 3.9 years) who have undergone UCLR between 1974 and 2024. Main Outcome Measures: The number of UCLR procedures each year. Independent Variables: Change-point analysis was used to identify changes in the number of UCLR surgeries over time among MLB and MiLB players. For MLB players, number of UCLR surgeries from 1974 to 2023 was analyzed, while for MiLB players, data starting from 1981 to 2024 were analyzed. Results: For MLB players, 3 change points were identified, occurring around 1989 (95% confidence interval [CI], 1988–1990), 2000 (95% CI, 2000–2000), and 2012 (95% CI, 2011–2017). For MiLB players, 3 change points were identified occurring around 2001 (95% CI, 2001–2001), 2009 (95% CI, 2008–2010), and 2013 (95% CI, 2013–2015). Conclusions: Overall, there has been a rise in the number of UCLR surgeries per year for the past 50 years in professional baseball, with distinct time points identified, representing increases in the number of UCLR surgeries each year. A higher number of UCLR surgeries are performed per year in the MiLB than in the MLB.
Gaze Patterns During Evaluation of Facial Attractiveness: An Eye‐Tracking Investigation
Fearington, Forrest W. , Pumford, Andrew D. , Dey, Jacob K. , Awadallah, Andrew S. , Dey, Jacob K

Mayo Clinic

The Laryngoscope | December 24, 2024 | Volume: 135 | Issue: 6 | Pages: 1995-2002

10.1002/lary.31967 | PMID 39716979 Get It

BackgroundObjective, controlled eye‐tracking measurement of gaze patterns during layperson evaluation of facial attractiveness is currently lacking.ObjectivesTo objectively investigate (1) where on the face laypeople direct their attention when assessing attractiveness compared with a control group, and (2) whether increased fixation on certain facial regions is associated with high attractiveness ratings.MethodsLay observers viewed a cohort of 40 faces with a diverse age, sex, and racial distribution. Observers were either allowed to free‐gaze without a specific task or rate facial attractiveness for 10 seconds per face while their gaze was recorded by an eye‐tracking system.ResultsForty‐seven observers assessed facial attractiveness (mean age 35.1 years (range 21–76), 62% female) and 57 observers free‐gazed at the facial photos without a specific task (mean age 35.5 years (range 22–66), 54% female). Preliminary analysis showed that sex of both the face and observer substantially influence gaze‐attractiveness associations (p < 0.05). Mixed effects analysis suggests that when males assessed female facial attractiveness, increased fixation time at the mouth correlated most strongly with high attractiveness (p = 0.001), whereas when females assessed male faces, increased fixation at the eyes (p < 0.001) and hair (p = 0.002) were most strongly associated with high ratings of attractiveness.ConclusionsIncreased gaze at the mouth in females and eyes and hair in males is associated with significantly higher ratings of attractiveness by observers of the opposite sex. Practitioners may want to pay special attention to these areas when designing an evidence‐based aesthetic treatment plan.Level of EvidenceNA Laryngoscope, 135:1995–2002, 2025
Baseline Kidney Function and the Effects of Dapagliflozin On Health Status in Heart Failure in DEFINE-HF and PRESERVED-HF
Ambrosy, Andrew P. , Patel, Shachi, Windsor, Sheryl L. , Husain, Mansoor, Inzucchi, Silvio E. , Kitzman, Dalane W, Kosiborod, Mikhail , Sauer, Andrew J , Borlaug, Barry A. , Kitzman, Dalane W. , McGuire, Darren K. , Shah, Sanjiv J , Sharma, Kavita, Umpierrez, Guillermo E.

Mayo Clinic

ESC Heart Failure | December 24, 2024 | Volume: 12 | Issue: 3 | Pages: 1676-1681

10.1002/ehf2.15184 | PMID 39716939 Get It

Abstract Aims Sodium–glucose co-transporter-2 (SGLT2) inhibitors improve health status and outcomes in the setting of heart failure (HF) across the range of ejection fraction (EF). Baseline kidney disease is common in HF, complicates HF management and is strongly linked to worse health status. This study aimed to assess whether the treatment effects of dapagliflozin on health status vary based on estimated glomerular filtration rate (eGFR). Methods and Results We conducted a pooled participant-level analysis of two double-blind, randomized trials, DEFINE-HF (n = 236) and PRESERVED-HF (n = 324), which evaluated dapagliflozin versus placebo. Both multicentre studies enrolled adults with HF, New York Heart Association Class II or higher, elevated natriuretic peptides, and an EF &lt; 40% in DEFINE-HF or &gt;45% in PRESERVED-HF. The primary exposure was eGFR. The main outcome was the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) at 12 weeks. Across both trials, there were 583 (99.3%) participants with a baseline eGFR. The median (25th, 75th) eGFR was 59 (46, 77) mL/min/1.73 m2. Dapagliflozin improved KCCQ-CSS at 12 weeks [placebo-adjusted difference, +5.0 points, 95% confidence interval (CI) 2.6–7.5; P &lt; 0.001], and this was consistent in participants with an eGFR ≥ 60 (+6.0 points, 95% CI 2.4–9.7; P = 0.001) and eGFR &lt; 60 (+4.1 points, 95% CI 0.5–7.7; P = 0.025) (P interaction = 0.46). The benefits of dapagliflozin on KCCQ-CSS remained robust across eGFR when modelled as a continuous variable (P interaction = 0.48). Conclusions Dapagliflozin led to early and clinically meaningful improvements in health status in HF patients, regardless of EF or baseline eGFR.
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials
Weiner, Michael W. , Kanoria, Shaveta , Miller, Melanie J. , Aisen, Paul , Conti, Catherine , Diaz, Adam , Flenniken, Derek , Harvey, Danielle , Jack, Clifford R. , Jagust, William J. , Morris, John C. , Nosheny, Rachel L. , Okonkwo, Ozioma C. , Perrin, Richard J. , Petersen, Ronald C. , Saykin, Andrew J. , Shaw, Leslie M. , Tosun, Duygu , Initiative, for the Alzheimer's Disease Neuroimaging, Jack, Clifford R , Saykin, Andrew J , Morris, John C , Harvey, Danielle J , Tosun, Duygu , Weiner, Michael W , Beckett, Laurel , Green, Robert C. , Lee, Edward B. , Nho, Kwangsik T. , Mindt, Mónica Rivera , Toga, Arthur W. , Veitch, Dallas P. , Initiative, for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14321 | PMID 39711072 Get It

Abstract The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to optimize and validate biomarkers for clinical trials while sharing all data and biofluid samples with the global scientific community. ADNI has been instrumental in standardizing and validating amyloid beta (Aβ) and tau positron emission tomography (PET) imaging. ADNI data were used for the US Food and Drug Administration (FDA) approval of the Fujirebio and Roche Elecsys cerebrospinal fluid diagnostic tests. Additionally, ADNI provided data for the trials of the FDA‐approved treatments aducanumab, lecanemab, and donanemab. More than 6000 scientific papers have been published using ADNI data, reflecting ADNI's promotion of open science and data sharing. Despite its enormous success, ADNI has some limitations, particularly in generalizing its data and findings to the entire US/Canadian population. This introduction provides a historical overview of ADNI and highlights its significant accomplishments and future vision to pioneer “the clinical trial of the future” focusing on demographic inclusivity. Highlights The Alzheimer's Disease Neuroimaging Initiative (ADNI) introduced a novel model for public‐private partnerships and data sharing. It successfully validated amyloid and Tau PET imaging, as well as CSF and plasma biomarkers, for diagnosing Alzheimer's disease. ADNI generated and disseminated vital data for designing AD clinical trials.
Autoimmune brainstem encephalitis: Clinical associations, outcomes, and proposed diagnostic criteria
Gilligan, Michael , Thakolwiboon, Smathorn , Orozco, Emma, Banks, Samantha A. , López‐Chiriboga, A. Sebastian , Tillema, Jan‐Mendelt , Mills, John R. , Pittock, Sean J. , Valencia-Sánchez, Cristina , Ζεκερίδου, Αναστασία , Dubey, Divyanshu , Dubey, Divyanshu , Pittock, S J , Banks, Samantha , Lopez-Chiriboga, A Sebastian , Valencia Sanchez, Cristina , Zekeridou, Anastasia , Dubey, Divyanshu , McKeon, Andrew , Dubey, Divyanshu , Gilligan, Michael , Thakolwiboon, Smathorn , Flanagan, Eoin P. , McKeon, Andrew

Mayo Clinic

Annals of Clinical and Translational Neurology | December 21, 2024 | Volume: 12 | Issue: 1 | Pages: 213-225

10.1002/acn3.52273 | PMID 39708293 Get It

AbstractObjectiveWe describe neurologic phenotype, clinical associations, and outcomes in autoimmune brainstem encephalitis.MethodsMedical records of neural‐IgG positive autoimmune brainstem encephalitis patients diagnosed at Mayo Clinic (January 1, 2006–December 31, 2022) were reviewed.ResultsNinety‐eight patients (57 male) were included. Median age of symptom onset was 51 years (range, 8 months‐85 years). Frequent presenting features were ≥1: diplopia (80%), ataxia (78%), dysarthria (68%), vestibulocochlear symptoms (67%), dysphagia (61%), nausea/vomiting (42%), and facial weakness (32%). Altered mental status (11%) was uncommon. Neural antibodies detected were as follows: KLHL‐11 (26 patients), GAD65 (high titer, 12), ANNA‐1 (anti‐Hu, 8), ANNA‐2 (anti‐Ri, 8), Ma2 (7), IgLON‐5 (6), AQP4 (6), MOG (4), glycine receptor (4), GQ1B (4), PCA‐1 (anti‐Yo, 4), DPPX (2), neurochondrin (2), neurofilament (2), NMDA‐R (2), AGNA‐1 (SOX‐1, 1), ANNA‐3 (DACH1, 1), amphiphysin (1), CRMP‐5 (1), ITPR‐1 (1), PCA‐Tr (DNER, 1), and PDE10A (1). Cancer was identified in 55 patients: germ cell (23 patients; 3 extra‐testicular), ductal breast adenocarcinoma (8), small cell carcinoma (6, lung 4), adenocarcinomas (6), neuroendocrine carcinoma (3), hematologic (2), squamous cell (2), and other (7). Median modified Ranking score (mRS) at last follow‐up was 3 (range, 0–6). Factors associated with poor outcome included abnormal brain MRI, bulbar symptoms, and elevated CSF IgG index. Kaplan–Meier analysis revealed faster progression to wheelchair in patients who were immunotherapy refractory and with elevated CSF IgG index. Diagnostic criteria for autoimmune brainstem encephalitis (definite and probable) are proposed.InterpretationAutoimmune brainstem encephalitis is a distinct clinical subphenotype of autoimmune encephalitis. Abnormal brain MRI, bulbar symptoms, and elevated CSF‐IgG index associate with poor outcome.